Genesis Co-Founder Michael Watkins Is Named One of the World’s Most Influential Business Thinkers
Michael Watkins, leadership transitions expert and best-selling author of the classic onboarding reference The First 90 Days, was named one of the world’s most influential business thinkers by Thinkers50. Among those also included in the prestigious rankings were W. Chan Kim, Renée Mauborgne, Roger Martin, Amy Edmondson, and Daniel Pink.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005452/en/
The First 90 Days and Master Your Next Move author Michael Watkins named one of the world’s most influential business thinkers. (Photo: Business Wire)
Thinkers50 identifies and ranks the top 50 management thinkers globally and announces them at their biannual Awards Gala, dubbed “the Oscars of Management Thinking” by the Financial Times. This year’s Thinkers50 rankings are the most diverse yet, with 19 women in the top 50, and 14 nationalities represented overall.
On receiving the news that he made the list Watkins said, “It is very gratifying to be included in the Thinkers50 rankings. To have the ideas to which I have devoted my career endorsed in this way is an honor. It also highlights the importance for leaders to learn how to navigate diverse career transitions and for companies to provide needed support for onboarding.”
Michael Watkins
Best known for his international best-seller The First 90 Days in which he outlines his framework for navigating successful career transitions, Watkins is the cofounder of Boston, MA-based leadership development consultancy, Genesis Advisers. He is the author of eleven books published by Harvard Business Review Press including Master Your Next Move: The Essential Companion to The First 90 Days (HBR Press, April 2019), as well as numerous articles on the subjects of leadership, organizational change, and negotiation. He is professor of Leadership and Organizational Change at the IMD Business School where he teaches two programs based on his First 90 Days® onboarding framework, as well as his Seven Seismic Shifts™ framework for managing the transition to enterprise leader. Prior to IMD, Watkins taught at INSEAD, Harvard Business School and Harvard University, where he earned his PhD in Decision Sciences.
Thinkers50
Launched in 2001, Thinkers50 was the first-ever global ranking of management thinkers. The List has been published every two years since and remains the premier ranking of its kind. Since its founding, the scope of Thinkers50 has broadened to include a range of activities that support the mission of providing innovative access to powerful business and management ideas.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005452/en/
Contact information
Michol J. Munns
Director of Marketing and Communications
Michol.munns@genesisadvisers.com
https://www.genesisadvisers.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
Illumynt Reports Q3 2025 Business Update17.10.2025 15:39:00 EEST | Press release
Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom